Zydus Lifesciences receives approval from USFDA to conduct Phase II(b) clinical trial for Usnoflas
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The company has paid an Interim Environmental Damage Compensation of Rs. 3.40 lakh to GPCB
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles
Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Morepen Laboratories approves hiving off of medical devices business
Subscribe To Our Newsletter & Stay Updated